Leptin Deficiency Contributes to the Pathogenesis of Alcoholic Fatty Liver Disease in Mice  by Tan, Xiaobing et al.
The American Journal of Pathology, Vol. 181, No. 10, October 2012
Copyright © 2012 American Society for Investigative Pathology.
Published by Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.ajpath.2012.06.013Gastrointestinal, Hepatobiliary, and Pancreatic Pathology
Leptin Deficiency Contributes to the Pathogenesis of
Alcoholic Fatty Liver Disease in MiceXiaobing Tan,* Xiuhua Sun,* Qiong Li,*
Yantao Zhao,† Wei Zhong,* Xinguo Sun,*
Wei Jia,*‡ Craig J. McClain,§¶ and
Zhanxiang Zhou*‡
From the Center for Translational Biomedical Research* and the
Department of Nutrition,‡ University of North Carolina at
Greensboro, North Carolina Research Campus, Kannapolis, North
Carolina; the College of Animal Sciences and Veterinary Medicine,†
Agricultural University of Hebei, Baoding, China; and the
Departments of Medicine, and Pharmacology and Toxicology,§
University of Louisville Alcohol Research Center, Louisville and
the Louisville Veterans Affairs Medical Center,¶ Louisville,
Kentucky
White adipose tissue (WAT) secretes adipokines,
which critically regulate lipid metabolism. The pres-
ent study investigated the effects of alcohol on adipo-
kines and the mechanistic link between adipokine
dysregulation and alcoholic fatty liver disease. Mice
were fed alcohol for 2, 4, or 8 weeks to document
changes in adipokines over time. Alcohol exposure
reduced WAT mass and body weight in association
with hepatic lipid accumulation. The plasma adi-
ponectin concentration was increased at 2 weeks, but
declined to normal at 4 and 8 weeks. Alcohol expo-
sure suppressed leptin gene expression in WAT and
reduced the plasma leptin concentration at all times
measured. There is a highly positive correlation be-
tween plasma leptin concentration and WAT mass or
body weight. To determine whether leptin deficiency
mediates alcohol-induced hepatic lipid dyshomeostasis,
mice were fed alcohol for 8 weeks with or without lep-
tin administration for the last 2 weeks. Leptin adminis-
tration normalized the plasma leptin concentration and
reversed alcoholic fatty liver. Alcohol-perturbed genes
involved in fatty acid -oxidation, very low-density li-
poprotein secretion, and transcriptional regulation
were attenuated by leptin. Leptin also normalized alco-
hol-reduced phosphorylation levels of signal trans-
ducer Stat3 and adenosine monophosphate–activated
protein kinase. These data demonstrated for the first
time that leptin deficiency in association with WAT
mass reduction contributes to the pathogenesis of alco-holic fatty liver disease. (Am J Pathol 2012, 181:1279–1286;
http://dx.doi.org/10.1016/j.ajpath.2012.06.013)
Alcoholic liver disease is traditionally described as three
progressive pathologic conditions: steatosis (fatty liver),
hepatitis, and cirrhosis.1 Alcoholic fatty liver is character-
ized by lipid droplet accumulation in the cytoplasm of
hepatocytes, and is one of the earliest pathologic altera-
tions in the liver. Accumulation of lipids in the hepato-
cytes makes the liver susceptible to inflammatory medi-
ators or other toxic agents, leading to further progression
to hepatitis and eventually to fibrosis. Alcohol consump-
tion may affect multiple pathways of hepatic lipid metab-
olism including de novo lipogenesis, fatty acid oxidation,
lipid uptake, and lipid export in the form of very low-
density lipoproteins.2,3 However, recent studies have
suggested that extrahepatic factors such as adiponectin
critically modulate hepatic lipid metabolism.4,5
White adipose tissue (WAT) is a major organ for body
fat storage, and also functions as an endocrine organ.6
The hormones secreted by WAT are adipokines, and two
of the most important adipokines related to energy ho-
meostasis are adiponectin and leptin. Both adiponectin
and leptin critically modulate hepatic lipid homeostasis
toward reduction of lipid content in the liver. Adiponectin
signaling in the liver leads to activation of the adenosine
monophosphate-activated protein kinase (AMPK) path-
way via adiponectin receptor.4–7 AMPK activation nega-
tively regulates the hepatic lipid level by stimulating fatty
acid oxidation and suppressing fatty acid influx and de
novo lipogenesis. Leptin critically regulates whole-body
energy homeostasis by inhibiting energy intake and stim-
ulating energy expenditure. Leptin signaling in the liver
Supported in part by grants R01AA018844 (Z.Z.), R01AA020212 (Z.Z.),
R37AA010762 (C.J.M.), RC2AA019385 (C.J.M.), and P01AA017103 (C.J.M.)
from the NIH and by the Veterans Administration (C.J.M.).
Accepted for publication June 11, 2012.
Supplemental material for this article can be found at http://ajp.
amjpathol.org or at http://dx.doi.org/10.1016/j.ajpath.2012.06.013.
Address reprint requests to Zhanxiang Zhou, Ph.D., The Center for Trans-
lational Biomedical Research and Department of Nutrition, University of North
Carolina at Greensboro, North Carolina Research Campus, 500 Laureate
Way, Ste 4226, Kannapolis, NC 28081. E-mail: z_zhou@uncg.edu.
1279
1280 Tan et al
AJP October 2012, Vol. 181, No. 10via leptin receptor b (LepRb) activates AMPK and signal
transducer Stat3 pathways.6,7 Mice lacking functional
leptin develop not only obesity but also fatty liver. There-
fore, adipose tissues via adipokine secretion significantly
affect lipid homeostasis in the liver.
Alcohol exposure has been shown to affect adipose
mass and adipokine secretion in both humans and ani-
mals. Patients with alcoholism have lower body mass
index (BMI) and fat mass (FM) but higher liver fat lev-
els.8–11 Studies in humans have also found that the se-
rum leptin concentration was reduced by either chronic
alcohol consumption or acute alcohol abuse.11–14
Chronic alcohol exposure in rodents reduced adipose
tissue weight,15–17 and serum adiponectin18–23 and lep-
tin24,25 concentrations in association with the develop-
ment of fatty liver. Administration of exogenous adiponec-
tin or stimulation of endogenous adiponectin production
attenuated alcoholic fatty liver in mice.18,19,23,26 These
studies indicate that adipokines critically regulate lipid
homeostasis at the adipose tissue–liver axis. The present
study reports that chronic alcohol exposure caused leptin
deficiency, and leptin administration for 2 weeks re-
versed alcohol-induced fatty liver in mice previously ex-
posed to alcohol for 6 weeks.
Materials and Methods
Animals and Alcohol Feeding Experiments
Male C57BL/6 mice were obtained from Harlan Labora-
tories, Inc. (Indianapolis, IN). All of the mice were treated
according to the experimental procedures approved by
the Institutional Animal Care and Use Committee. At age
4 months, mice were pair-fed a modified Lieber-DeCarli
alcohol or isocaloric maltose dextrin control liquid diet for
up to 8 weeks in a stepwise procedure. Caloric content of
the alcohol diet was 16% protein, 12% carbohydrate,
34% fat, and 38% ethanol (Sigma-Aldrich Corp., St.
Louis, MO). The ethanol content (w/v) in the diet was
4.8% (34% of total calories) for the first 2 weeks, and was
increased by 0.2% every 2 weeks, reaching 5.4% (38% of
total calories) for the last 2 weeks. On the basis of our
observations, this stepwise feeding protocol improves
the performance of the mouse model of alcohol feeding,
as indicated by reduced mortality. Two sets of animal
experiments were performed. Experiment 1 was per-
formed to determine adipokine production in association
with development of alcoholic liver disease, and mice
were subjected to alcohol exposure for 2, 4, or 8 weeks.
Experiment 2 was performed to determine the role of
leptin in alcoholic liver disease because leptin deficiency
was detected in experiment 1. Mice were subjected to
alcohol exposure for 8 weeks, with leptin (purity 95%;
ProSpec, East Brunswick, NJ) administration at 0.5 mg/d
per kilogram body weight or saline solution as vehicle, via
subcutaneous osmotic minipump (ALZET Osmotic Pump;
DURECT Corp., Cupertino, CA) for the last 2 weeks.Blood Parameters
Blood glucose concentration was measured using a
OneTouch Ultra2 Blood Glucose Meter (LifeScan, Inc.,
Milpitas, CA), and ketone bodies using PTS PANELS
Ketone Test Strips (Polymer Technology Systems, Inc.,
Indianapolis, IN). Plasma alanine aminotransferase activ-
ity and triglyceride and cholesterol concentrations were
determined using Infinity Reagents (Thermo Fisher Sci-
entific, Inc., Middletown, VA). Plasma free fatty acids
(FFAs) were quantified using an FFA Quantification Kit
(BioVision, Inc., Milpitas, CA). Plasma leptin and adi-
ponectin concentrations were measured using commer-
cial mouse enzyme-linked immunosorbent assay kits
(Millipore Corp., Billerica, MA).
Liver Histopathologic and Lipid Concentrations
Liver tissues were fixed in 10% formalin and embedded
in paraffin. Tissues were cut into 5-m sections and pro-
cessed for H&E staining and Sirus Red staining. Quanti-
tative assay of lipids was conducted by measuring tri-
glyceride, cholesterol, and FFA concentrations in the
liver. Hepatic lipids are extracted by homogenizing liver
tissue in chloroform using 1% Triton X-100. The organic
extracts were air dried, vacuumed, and dissolved in 1%
Triton X-100. Triglyceride, cholesterol, and FFA concen-
trations in extracts were determined using commercial
kits (see Blood Parameters).
Quantitative RT-PCR
The total RNA was isolated from liver or WAT using the
TRIzol method (Life Technologies Corp., Grand Island,
NY), and reverse transcription was conducted using the
TaqMan Reverse Transcription Reagents Kit (Applied
Biosystems, Inc., Foster City, CA). The forward and re-
verse primers (Table 1) were designed using Primer Ex-
press Software v3.0.1 (Applied Biosystems), and quanti-
tative RT-PCR (RT-qPCR) analysis with SYBR Green PCR
master mix (Qiagen, Inc., Valencia, CA) was performed
using a PRISM 7500 Sequence Detection System (Ap-
plied Biosystems). Data were normalized to -actin ex-
pression, and are given as fold changes, setting the
values of pair-fed mice at 1.
Immunoblot Analysis
Whole protein lysates of liver were extracted using 10%
Nonidet P-40 lysis buffer supplemented with 1% protease
inhibitor cocktail and 1% phenylmethylsulfonyl fluoride.
Aliquots containing 60 g proteins were loaded onto 10%
SDS-PAGE, transblotted onto polyvinylidene difluoride
membrane, blocked using 5% nonfat dry milk in Tris-
buffered saline solution with 0.1% Tween-20, and incu-
bated with rabbit anti-pStat3, Stat3, pAMPK, AMPK (Cell
Signaling Technology, Inc., Danvers, MA), PPAR- (per-
oxisome proliferator-activated receptor-), HNF-1 (he-
patocyte nuclear factor-1), C/EBP- (CCAAT/enhancer
binding protein), or -actin antibody (Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA). The membrane was then
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anti-rabbit IgG. The bound complexes were detected via
chemiluminescence. The immunoblot bands were quan-
tified via densitometry analysis, and the ratio to -actin
was calculated and is given as fold changes, setting the
values of pair-fed mice at 1.
Statistical Analysis
All data are given as mean  SD. The results were ana-
lyzed using the one-sample t-test for two groups, and
one-way analysis of variance with Turkey post hoc com-
parison for more than two groups. Correlation coeffi-
cients, analyzed using Prime 3, were used to determine
linear association between plasma leptin concentration
and WAT mass or body weight. In all statistical tests, P 
0.05 was considered significant.
Results
Chronic Alcohol Exposure Induced Leptin Deficiency
in AssociationWith Fatty Liver Disease
Alcohol exposure for 2, 4, and 8 weeks caused liver
damage that was time-dependent (Figure 1A). Lipid
droplet accumulation in the liver is the major pathologic
Table 1. Primer Sequences for Real-Time RT-PCR
Gene
GeneBank
accession
no. Sequences (Forward/Reverse)
ACADL NM_007381 5=-TCTTTTCCTCGGAGCATGACA-3=
5=-GACCTCTCTACTCACTTCTCCAG-3=
ACOX1 NM_015729 5=-TCCAGACTTCCAACATGAGGA-3=
5=-CTGGGCGTAGGTGCCAATTA-3=
ApoB NM_009693 5=-TTGGCAAACTGCATAGCATCC-3=
5=-TCAAATTGGGACTCTCCTTTAGC-3=
C/EBP- NM_007678 5=-CAAGAACAGCAACGAGTACCG-3=
5=-GTCACTGGTCAACTCCAGCAC-3=
FABP1 NM_017399 5=-ATGAACTTCTCCGGCAAGTACC-3=
5=-CTGACACCCCCTTGATGTCC-3=
FATP2 NM_011978 5=-TCCTCCAAGATGTGCGGTACT-3=
5=-TAGGTGAGCGTCTCGTCTCG-3=
FATP5 NM_009512 5=-CTACGCTGGCTGCATATAGATG-3=
5=-CCACAAAGGTCTCTGGAGGAT-3=
HNF-1 NM_009327 5=-GACCTGACCGAGTTGCCTAAT-3=
5=-CCGGCTCTTTCAGAATGGGT-3=
HNF-4 NM_008261 5=-GCCTTCTGCGAACTCCTTCTG-3=
5=-GGGACGATGTAGTCATTGCCT-3=
CPT1a NM_013495 5=-CTCCGCCTGAGCCATGAAG-3=
5=-CACCAGTGATGATGCCATTCT-3=
Leptin NM_008493 5=-GAGACCCCTGTGTCGGTTC-3=
5=-CTGCGTGTGTGAAATGTCATTG-3=
LepR-b NM_146146 5=-TGGTCCCAGCAGCTATGGT-3=
5=-ACCCAGAGAAGTTAGCACTGT-3=
MTTP NM_008642 5=-TCAAGAGAGGCTTGGCTAGCTT-3=
5=-GCCTGGTAGGTCACTTTACAATCC-3=
PPAR- NM_011144 5=-AGAGCCCCATCTGTCCTCTC-3=
5=-ACTGGTAGTCTGCAAAACCAAA-3=
PPAR- NM_011146 5=-TCGCTGATGCACTGCCTATG-3=
5=-GAGAGGTCCACAGAGCTGATT-3=
-Actin NM_007393 5=-GGCTGTATTCCCCTCCATCG-3=
5=-CCAGTTGGTAACAATGCCATGT-3=change at 2 weeks. At 4 and 8 weeks, the number andsize of the lipid droplets in the hepatocytes gradually
increased, and inflammatory cell infiltration was fre-
quently found. In contrast, alcohol exposure significantly
reduced epididymal and subcutaneous WAT mass at all
three times measured (Figure 1B). In comparison with a
gradual increase in WAT weight in pair-fed mice, alcohol-
fed mice maintained a low WAT weight. The body weight
of alcohol-fed mice was lower than that of pair-fed mice at
all three times measured (data not shown).
To determine whether alcohol-induced lipodystrophy
leads to alterations in adipokine secretion, plasma adi-
ponectin and leptin levels were measured. Plasma adi-
ponectin levels in pair-fed mice did not change at any times
measured (Figure 2A). Alcohol exposure for 2 weeks in-
creased the plasma adiponectin concentration, but it de-
clined to normal at 4 and 8 weeks. The plasma leptin con-
centration in pair-fed mice showed a significant increase at
4 and 8 weeks in comparison with that at 0 and 2 weeks
(Figure 2A). Alcohol exposure reduced the plasma leptin
concentration by 40%, 20%, and 59% at 2, 4, and 8 weeks,
respectively, compared with that at 0 week. RT-qPCR anal-
ysis demonstrated that alcohol exposure for 8 weeks dra-
matically down-regulated leptin gene expression in both
epididymal and subcutaneous WATs (Figure 2B). Correla-
tion analysis showed highly positive correlation coefficients
between plasma leptin concentration and epididymal and
subcutaneous WAT mass and body weight (Figure 2C).
Effects of Leptin Administration on Body
Weight, Liver Weight, Adipose Tissue
Weight, and Blood Metabolites
To determine the role of leptin deficiency in the patho-
genesis of alcoholic fatty liver, leptin was administered to
Figure 1. Alcohol-induced adipose mass reduction in association with liver
damage in mice fed with alcohol for 2, 4, or 8 weeks. A: Liver histopathologic
analysis (H&E) revealed lipid droplets (arrows) and inflammatory cell infil-
tration (arrowheads). CV, central vein. B: WAT mass. Results are given as
†mean  SD (n  6 to 10). *P  0.05 versus pair-fed mice (t-test); P  0.05
versus 2 weeks (analysis of variance).
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administration normalized the alcohol-decreased plasma
leptin concentration and stimulated hepatic LepRb gene
expression (Figure 3A), although alcohol alone also up-
regulated hepatic LepRb (Figure 3B). Effects of leptin
administration on routine parameters are given in Table 2.
Alcohol exposure with or without leptin administration
reduced body weight, whereas liver weight was reduced
only by alcohol plus leptin. As a consequence, the liver–
body weight ratio was increased by alcohol exposure,
which was partially reversed by leptin. Epididymal WAT
weight and its ratio to body weight were reduced by
alcohol, and the reduction was promoted by leptin.
Alcohol exposure significantly elevated the plasma al-
anine aminotransferase concentration, which was nor-
malized by leptin. Alcohol exposure decreased blood
glucose and cholesterol concentrations, and increased
the plasma ketone body concentration; these altera-
tions were not affected by leptin. However, leptin ad-
ministration normalized alcohol-reduced plasma FFA
concentrations.
Figure 3. Plasma leptin concentration (A) and hepatic LepRbmRNA level (B)
in mice fed with alcohol for 8 weeks with or without leptin administration for
the last 2 weeks. Results are given as mean  SD (n  6 to 10 in A; n  4
†in B). *P  0.05 versus pair-fed mice (PF) (analysis of variance); P  0.05
versus alcohol-fed mice (AF) (analysis of variance).Leptin Administration Reverses Alcohol
Exposure-Induced Lipid Accumulation
in the Liver
Alcohol exposure for 8 weeks caused lipid droplet accu-
mulation in the liver, which was attenuated by leptin (Fig-
ure 4A). Quantitative assay of hepatic lipids demon-
strated that alcohol exposure significantly increased the
concentrations of triglycerides, cholesterol, and FFAs in
the liver (Figure 4B). Leptin administration normalized the
concentrations of hepatic triglycerides and FFAs, but did
not affect the alcohol-elevated cholesterol concentration.
To exclude the possibility that leptin may affect liver fi-
brogenesis, the hepatic collagen level was assessed us-
ing Sirius Red staining. Neither alcohol feeding alone nor
alcohol feeding plus leptin administration caused signif-
icant collagen accumulation in the liver (see Supplemen-
tal Figure S1 at http://ajp.amjpathol.org).
Leptin Administration Improves Alcohol
Exposure–Dysregulated Hepatic Genes
Related to Lipid Metabolism
The relative mRNA levels of hepatic genes related to lipid
metabolism are given in Table 3. Among three fatty acid
transport genes, FABP1 was down-regulated by alcohol
regardless of leptin administration, whereas FATP2 was
up-regulated by leptin. Alcohol exposure down-regulated
all three genes related to fatty acid -oxidation, CPT1a,
ACADL, and ACOX1, which was normalized by leptin. Lep-
tin administration also normalized alcohol-down-regulated
very low-density lipoprotein assembly genes MTTP and
ApoB. Among the five transcription factors related to lipid
metabolism regulation, alcohol exposure down-regulated
C/EBP-, HNF-1, PPAR-, and PPAR-, and leptin nor-
malized the expression levels of the first three but not
PPAR-. The HNF-4 gene was not affected by either
alcohol or leptin. Immunoblot analysis demonstrated that
leptin administration reversed alcohol-reduced protein
Figure 2. Effects of alcohol on plasma adiponectin and
leptin levels in mice fed with alcohol for 2, 4, or 8 weeks. A:
Plasma adiponectin and leptin concentrations. B:WAT leptin
mRNA levels. C: Correlation of plasma leptin concentration
with WAT mass or body weight. Correlation was analyzed
using Prime 3. Results are given as mean  SD (n 6 to 10).
*P  0.05 versus pair-fed mice (t-test); †P  0.05 versus 0
week (analysis of variance).levels of PPAR- and HNF-1 (Figure 5A). However, the
ariance
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regardless of leptin administration. Immunoblot analysis
also showed that the phosphorylation levels of Stat3 and
AMPK, the major molecules mediating leptin signaling,
were reduced after alcohol exposure, but were normal-
ized by leptin administration (Figure 5B).
Discussion
Alcohol consumption has been shown to modulate
plasma adipokine levels, in particular adiponectin. Alco-
hol exposure in mice decreased the serum adiponectin
concentration in a time-dependent manner, whereas ad-
ministration with mouse recombinant adiponectin attenu-
ated alcohol-induced fatty liver and inflammation.18 The
decrease in plasma adiponectin concentration was also
found in other animal models including rats and mi-
cropigs.19–23 Elevation of the plasma adiponectin con-
centration was associated with protective effects of di-
etary supplementation with saturated fat, rosiglitazone, or
resveratrol against alcoholic fatty liver.19,23,26 However,
Figure 4. Liver histopathologic and lipid concentrations in mice fed with
alcohol (AF) for 8 weeks with or without leptin administration for the last 2
weeks. A: Histopathologic analysis (H&E) revealed lipid droplets (arrows)
and inflammatory cell infiltration (arrowhead). CV, central vein. B: Liver
Table 2. Effects of Chronic Alcohol Exposure and Leptin Admin
Blood Metabolites
Measurements PF
Food intake (g/d per mouse) 10.36 
Alcohol intake (g/d per mouse) NA
Body weight (g) 29.77 
Liver weight (g) 1.25 
Epididymal WAT weight (g) 1.28 
Liver–body weight ratio 4.17 
Epididymal WAT–body weight ratio 4.27 
Plasma ALT (U/mL) 24.36 
Blood glucose (mg/dL) 277.0 
Blood ketone bodies (mg/dL) 4.90 
Plasma triglycerides (mg/dL) 75.45 
Plasma cholesterol (mg/dL) 91.29 
Plasma free fatty acids (mmol/L) 0.80 
Mice were pair-fed alcohol or isocaloric maltose dextran for 8 weeks
Data are given as mean  SD (n  6–10).
*P  0.05 versus PF (ANOVA).
†P  0.05 versus AF (ANOVA).
AF, alcohol-fed; ALT, alanine aminotransferase; ANOVA, analysis of vlipid concentrations. Results are given as mean SD (n 6 to 10). *P 0.05
versus pair-fed mice (PF) (analysis of variance).there are controversial reports on the effect of alcohol on
adiponectin. A recent study demonstrated that high dos-
ages of alcohol alone or plus overnutrition increased the
plasma adiponectin concentration.27 Clinical studies
have also demonstrated that the serum adiponectin con-
centration correlated well with daily alcohol consumption
and liver injury, but declined during alcohol abstinence.28
The present study demonstrated that alcohol exposure
did not reduce the plasma adiponectin concentration,
although a dramatic reduction in adipose mass was
found. A previous report showed that adipose tissue re-
duction in iNOS null mice was associated with hypolep-
on Body Weight, Liver Weight, Epididymal WAT Weight, and
AF AF/Leptin
11.02  0.76 10.67  1.47
0.59  0.04 0.56  0.07
24.05  1.40* 22.60  0.52*
1.30  0.07 1.09  0.05*
0.42  0.04* 0.18  0.04*†
5.41  0.14* 4.83  0.14*
1.74  0.12* 0.78  0.18*†
65.82  9.60* 31.50  11.18†
221.0  19.1* 204.7  26.1*
7.08  1.65* 8.34  1.25*
76.98  21.32 57.83  20.40
59.81  11.24* 47.85  9.66*
0.43  0.21* 0.72  0.21†
resence or absence of external leptin for the last 2 weeks.
; PF, pair-fed; WAT, white adipose tissue.
Table 3. Effects of Leptin Administration on Hepatic Genes
Related to Lipid Metabolism
Measurements PF AF AF/Leptin
Fatty acid
transport
FABP1 1.006  0.13 0.41  0.13* 0.33  0.09*
FATP2 1.005  0.12 0.98  0.29 1.50  0.29*†
FATP5 1.003  0.10 0.98  0.10 1.23  0.17
Fatty acid
-oxidation
CPT1a 1.001  0.05 0.53  0.02* 1.06  0.27†
ACADL 1.009  0.16 0.70  0.15* 1.007  0.11†
ACOX1 1.001  0.05 0.58  0.14* 0.86  0.26†
VLDL assembly
MTTP 1.04  0.35 0.64  0.09* 0.71  0.11
ApoB 1.003  0.10 0.76  0.02* 1.17  0.20†
Transcription
factors
C/EBP- 1.004  0.11 0.67  0.02* 0.93  0.08†
HNF-1 1.008  0.15 0.56  0.12* 0.84  0.12†
HNF-4 1.01  0.21 1.07  0.15 1.27  0.27
PPAR- 1.004  0.11 0.62  0.09* 0.93  0.05†
PPAR- 1.007  0.14 0.27  0.16* 0.16  0.06*
Mice were pair-fed alcohol on isocaloric maltose dextran for 8 weeks
in the presence or absence of external leptin for the last 2 weeks.
Gene expression was analyzed using quantitative RT-PCR.
Data are given as mean  SD (n  4).
*P  0.05 versus PF (ANOVA).
†P  0.05 versus AF (ANOVA).istration
0.83
1.76
0.08
0.21
0.36
0.59
7.19
45.4
1.59
14.12
17.88
0.15
in the pAF, alcohol-fed; ANOVA, analysis of variance; PF, pair-fed; VLDL, very
low-density lipoprotein.
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was normal.29 These data suggest that the plasma adi-
ponectin concentration does not correlate with WAT
mass.
Alcohol abuse affected the serum leptin concentration
in both human and animal studies. Serum leptin concen-
trations in patients with alcoholism correlate well with BMI
and FM.11–14,24,25 Patients with alcoholism with lower BMI
and FM had decreased serum leptin concentrations,11,12
whereas those with greater BMI and FM had increased
serum leptin concentrations.30 Of importance, lower BMI
and FM in patients with alcoholism were associated with
lipid accumulation in the liver.11,12 An animal study dem-
onstrated that acute alcohol exposure in rats reduced the
plasma leptin concentration in a dose-dependent man-
ner.24 Chronic alcohol exposure in rodents reduced the
plasma leptin concentration in association with reduction
of WAT mass and accumulation of lipids in the liver or
bone marrow.16,17,25 The present study demonstrated
that reduction of the plasma leptin concentration was
association with alcoholic fatty liver, and highly positive
correlations occur between the plasma leptin concentra-
tion and WAT mass and body weight. These findings
suggest that hypoleptinemia is associated with WAT re-
duction and development of alcoholic fatty liver.
Leptin critically regulates hepatic lipid homeostasis,
and animals with either leptin mutation, as in ob/ob mice,
or leptin receptor mutation, as in db/db mice and Zucker
(fa/fa) rats, develop fatty liver in association with early
onset of obesity and insulin resistance.31 Alcohol expo-
sure caused more lipid accumulation and liver injury in
Zucker (fa/fa) rats than in wild-type rats.32 Hypoleptine-
mia in patients with lipodystrophy contributes to fatty liver
and insulin resistance.33–38 Leptin therapy for up to 18
months in these patients significantly reduced hepatic
volume and triglyceride contents, and improved patho-
logic alterations in liver biopsy specimens including ste-
atosis, ballooning injury, and parenchymal inflamma-
tion.33–35 Recent studies also have demonstrated that
leptin therapy normalized hepatic triglyceride concentra-
tion and reversed deadly consequences in both types I
Figure 5. Protein levels of PPAR-, HNF-1, and C/EBP- in the liver of
mice fed with alcohol (AF) for 8 weeks with or without leptin administration
for the last 2 weeks. A: Immunoblot analysis of PPAR-, HNF-1, and
C/EBP-. B: Immunoblot analysis of total and pStat3 and p-AMPK. Band inten-
sity was quantified using densitometry analysis, and the ratio to -actin was
calculated by setting the value of pair-fed mice (PF) at 1. Results are given as
mean  SD (n  3). *P  0.05 versus PF mice (analysis of variance).and II diabetes.36–38 These findings suggest that leptinhas potent antisteatotic and antidiabetic activities. The
present study demonstrated that leptin administration
ameliorated alcoholic fatty liver and corrected multiple
lipid metabolic pathways. While up-regulating genes of
fatty acid -oxidation is likely a major mechanism under-
lying leptin action, leptin also attenuated alcohol-induced
down-regulation of MTTP and ApoB. Furthermore, leptin
normalized alcohol-induced down-regulation of tran-
scription factors such as PPAR- and HNF-1. Knockout
of either PPAR- or HNF-1 causes fatty liver.39,40 The
present study and other previously published reports
have demonstrated that reactivation of PPAR- via di-
etary supplementation with zinc or PPAR- agonist atten-
uates alcoholic fatty liver.16,41 The present study also
demonstrated that leptin administration abrogated the
inhibitory effects of alcohol on AMPK and Stat3 signal
pathways. Inhibition of AMPK has been reported to me-
diate alcohol action in the liver, and reactivation of AMPK
was associated with prevention of alcoholic fatty liver by
dietary supplementation with rosiglitazone or resvera-
trol.23,26 Recent studies also showed that activation of
Stat3 mediates the protective effects of IL-6 and IL-22 on
alcoholic liver injury.42,43 All of these studies suggest that
AMPK and Stat3 are important molecular targets for ther-
apeutic intervention in alcoholic fatty liver disease.
Leptin has been implicated in multiple cell functions
including innate and adaptive immunity, liver regenera-
tion, and fibrogenesis. Leptin treatment attenuates alco-
hol-induced apoptosis and production of proinflamma-
tory cytokines and TGF- in HepG2 cells.44,45 Leptin
administration also attenuated TNF- production and he-
patocyte apoptosis in a mouse model of CCl4 hepatotox-
icity.46 Inhibition of oxidative stress was associated with
the protective effects of leptin in both in vivo and in vitro
studies.47,48 Leptin-deficient rats have lower levels of me-
tallothionein and zinc in the liver, which accounts for the
susceptibility to alcohol-induced steatohepatitis.32 In-
deed, our previous studies demonstrated that metallo-
thionein and zinc suppress alcohol-induced oxidative
stress, thereby preventing alcoholic liver injury.16,48,49
Leptin is also involved in liver fibrogenesis. Leptin-defi-
cient ob/ob mice failed to develop liver fibrosis in either a
methionine/choline deficiency or a CCl4 model.
50 How-
ever, clinical studies with leptin therapy for 4 to 18 months
improved the NASH (nonalcoholic steatohepatitis) score
without affecting the fibrosis score in liver biopsy.35 It
should be emphasized that leptin administration in the
present study was performed on the basis of the patho-
physiologic condition of hypoleptinemia. Normalizing the
plasma leptin concentration in alcohol-fed mice reversed
alcoholic fatty liver without affecting liver fibrogenesis.
In conclusion, leptin deficiency was associated with
reduction of WAT mass in a mouse model of alcoholic
fatty liver disease. Leptin administration attenuated alco-
hol-induced hypoleptinemia and hepatic lipid accumula-
tion in association with normalization of alcohol-induced
down-regulation of hepatic genes involved in lipid metab-
olism such as fatty acid oxidation, very low-density lipo-
protein secretion, and related transcription factors. Leptin
administration reversed alcohol-suppressed phosphory-
lation of AMPK and Stat3 in the liver. These findings
Leptin Deficiency in Alcoholic Steatosis 1285
AJP October 2012, Vol. 181, No. 10suggest that leptin deficiency in association with WAT
mass reduction may contribute to the pathogenesis of
alcoholic fatty liver disease.
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